the aid library

LIST OPTIONS

Filter

5817

Human Resources for Health in Ethiopia

The Collaborative Africa Budget Reform Initiative (CABRI) (2016) C1

Ethiopia has seen high economic growth over the last decade, but remains a poor country with a high burden of disease. It has made considerable health gains in recent years, mainly by having health policies that focus on extending primary healthcare, using health extension workers. It... more

Download (174)

View PDF (88)

Air quality and health

Minnesota Pollution Control Agency (2024) CC

Exposure to air pollution can affect everyone’s health. When we breathe in air pollutants, they can enter our bloodstream and contribute to coughing or itchy eyes and cause or worsen many breathing and lung diseases, leading to hospitalizations, cancer, or even premature death. Minnesota’s ai... more

Download (287)

View PDF (399)

A Decision Makers Guide: Medical Planning and Response for a Nuclear Detonation

U.S. Department of Health & Human Services (2017) C1

Successful detonation of an improvised nuclear device (IND) would be a catastrophic event, causing an unprecedented number of injuries and lives lost, as well as economic, political, and social disruption. However, an effective medical response and an infrastructure prepared to protect itself from f... more

Download (95)

View PDF (101)

Substance Use/Misuse

youth.gov Interagency Working Group on Youth Programs (IWGYP) (2024) CC

The Youth.gov webpage on "Substance Use/Misuse" provides information and resources about preventing and addressing substance abuse among youth. It highlights risk factors, prevention strategies, and support programs designed to reduce substance use and its negative impacts on young people. The site ... more

Download (335)

View PDF (446)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (170)

View PDF (188)

More time or more money to improve nutrition in Benin Republic?

M. C. D. N. Vodouhe, L. Fakambi Institut National des Recherches Agricoles du Bénin (INRAB) (2015) C2

Children malnutrition eradication in developing countries is a real challenge, especially among vulnerable population. There are so many effort towards women (who are the main care providers) socio-economic situation in order to improve their children nutrition. This article aims to identify the ... more

Download (225)

View PDF (278)

Climate change and communicable diseases: a manual for health workers

World Health Organization. Regional Office for Europe (2011) C_WHO

There is a broad consensus nowadays that the Earth is warming up as a result of greenhouse gas emissions caused by anthropogenic activities. It is also clear that current trends in the fields of energy, development and population growth will lead to continuous and ever more dramatic climate change. ... more

External Link

Newborn Care Videos: The Hot Baby

Global Health Media Project (2014) CC

This film shows the baby with a high body temperature: how to examine the baby, cool the baby, and determine if the baby is sick and needs referral (or, in cases where there is no referral option, how to treat the baby). http://globalhealthmedia.org/newborn/videos/the-hot-baby/

External Link

Dengue Prevention animation

Scientific Animations Without Borders (SAWBO) (2015) C2

Short animation on Dengue prevention and control.

Download (761)

View PDF (823)

COES – Febre Amarela INFORME – Nº 34 /201 7

Ministério da Saúde Secretaria de Vigilância em Saúde, Brazil (2017) C_WHO

Download (169)

View PDF (194)

Dengue Cheat Sheet

Centers for Disease Control and Prevention CDC (2015) C_CDC

Quick reference guide on clinical management of patients with Dengue

Download (238)

View PDF (225)

Poster (print): Dengue Warning Signs

World Health Organisation (WHO) (2023) C_WHO

DOWNLOAD (1.13 MB) Many people with dengue can be cared for at home with adequate rest and hydration. But, if you experience any warning signs, go immediately to the nearest medical center.

Download (457)

View PDF (251)

El dengue durante el embarazo

Centers for Disease Control and Prevention CDC CDC United States (2018) CC

El dengue durante el embarazo

Download (1190)

View PDF (1655)

Planificación de la movilización y comunicación social para la prevención y el control del dengue - GUÍA PASO A PASO

Parks, Will; Lloyd, Linda ORGANIZACIÓN MUNDIAL DE LA SALUD, ORGANIZACIÓN PANAMERICANA DE LA SALUD (2004) C_WHO

External Link

Febre amarela: Ministério da Saúde atualiza casos no país 28 de Março de 2018

Ministerio da Saude, Brazil (2018) C1

Download (666)

View PDF (979)

Atualização sobre a investigação de casos suspeitos de febre amarela silvestre , Minas Gerais, 2017 (05 de april 2017)

Secretaria de estado de Saud de Minas Gerais, Brasil (2017) C1

External Link

History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review

Souza Salles, T.; T. da Encarnação Sá-Guimarães, E. Seam Lima de Alvarenga et al. (2018) CC

Parasites & Vectors volume 11, Article number: 264 (2018) Dengue creates a staggering epidemiological and economic burden for endemic countries. Without a specific therapy and with a commercial vaccine that presents some problems relative to its full effectiveness, initiatives to improve vector... more

External Link

Epidemiology of dengue in SAARC territory: a systematic review and meta-analysis

Dhan Bahadur Shrestha, Pravash Budhathoki, Bipana Gurung et al. (2022) CC

Parasites & Vectors volume 15, Article number: 389 (2022) Dengue is one of the common arboviral infections and is a public health problem in South East Asia. The aim of this systematic review and meta-analysis was to evaluate the prevalence and distribution of dengue in SAARC (South Asian Associ... more

Download (798)

View PDF (1186)

Dengue Situation Update December 642

World Health Organization WHO, Regional Office for Western Pacific (2022) C_WHO

24 March 2022

External Link

Manejo clínico de la fiebre amarilla en la Región de las Américas. Experiencias y recomendaciones para los servicios de salud

Pan American Health Organization PAHO (2023) CC

Las olas de transmisión de la fiebre amarilla ocurridas en la Región de las Américas entre el 2016 y el 2018 causaron el mayor número de casos humanos y epizoóticos registrados en varios decenios. La fiebre amarilla es una enfermedad hemorrágica viral grave que representa un desafío para el p... more